The HMBOX1 Knouckout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This product enables loss-of-function studies of HMBOX1 (homeobox containing 1), a gene encoding a homeobox transcription factor. The polyclonal format provides a heterogeneous pool of edited cells, offering a robust model that avoids clonal selection bias. CRISPR/Cas9-mediated disruption of the target locus creates a versatile knockout system for investigating HMBOX1-dependent regulatory mechanisms in cancer biology.
The host A-549 cell line, established from the lung adenocarcinoma of a 58-year-old male, is a widely employed model for alveolar type II epithelium and non-small cell lung cancer research. These adherent epithelial cells retain key oncogenic features and aberrant signaling pathways characteristic of lung adenocarcinoma. The knockout in this cellular background provides a physiologically relevant system to examine HMBOX1??s role in lung carcinogenesis, tumor suppression, and epithelial homeostasis.
HMBOX1 functions as a transcriptional repressor that negatively regulates NF-??B signaling by binding to TANK, thereby inhibiting NF-??B activation and suppressing transcription of downstream targets such as Bcl-2, Bax, cyclin D1, and c-Myc. It also modulates Wnt/??-catenin signaling through direct interaction with ??-catenin and influences telomere maintenance via association with TRF1 and TRF2. Upstream regulators include p53, ??-catenin, and TNF-??. Through these interactions, HMBOX1 coordinates apoptosis, proliferation, and genomic stability pathways, underscoring its potential as a tumor suppressor.
In the A-549 lung adenocarcinoma context, HMBOX1 knockout permits dissection of its tumor suppressor functions. Loss of HMBOX1 may lead to heightened NF-??B activity, increased anti-apoptotic protein expression, and enhanced proliferation, mimicking cancer progression. This model is valuable for exploring HMBOX1??s impact on drug sensitivity, Wnt/??-catenin target gene regulation, and telomere integrity. It also provides insights into HMBOX1-related mechanisms in hepatocellular carcinoma and gastric cancer, facilitating comparative oncology studies.
This polyclonal knockout population is suitable for a broad range of assays. Western blotting and RT-qPCR can quantify key pathway components, while NF-??B luciferase reporter assays gauge transcriptional activity. Apoptosis assays (caspase-3/7) and MTT proliferation assays reveal effects on cell death and growth. Scratch wound healing assays assess migration, RNA-seq defines transcriptomic changes, and ChIP-qPCR or co-immunoprecipitation confirm molecular interactions. For further information, please contact Ascent Research.
